This week, we will discuss the first iteration of KDIGO’s 2025 guidelines on ADPKD. These guidelines are a result of a decade of global collaboration between physicians, researchers, advocates, and patients. The guidelines incorporate ADPKD-specific care as well as many general CKD management practice points.
This week, we will celebrate in advance World Kidney Day by discussing the results of OBInutuzumab in active lupus nephritis. The LUNAR trial (rituximab versus placebo) was “almost” positive, but not quite there. Would Obi overpower its cousin ritux? ✨
This week, we will continue with February’s aldosterone leitmotif: do mineralocorticoid receptor antagonists (MRAs) truly blind the diagnostic in unilateral hypraldosteronism? Is this the article the mythbuster? Draw your own conclusions
This week, we will discuss the origins of primary hyperaldosteronism in normotensive patients. Could this undetected anomaly be the cause of idiopathic hypertension and CKD?
2023 brought us has dogma shredding data on hyponatremia and the importance of different diuretics. It has new therapies for old diseases like IgA and hypertension. New drugs for new diseases like inaxaplin for AMKD. And it has new data on old debates like what IVF is best and do thiazides really prevent kidney stones. It is a great list. Dig in!
TenTweetNephJC on AIN = TenXNephJC on AIN = XXNephJC on AIN…? Twitter not being called twitter is confusing.
Welcome👋to #TenTweetNephJC!
— Nephrology Journal Club (@NephJC) September 28, 2023
"We seek it here,we seek it there.."
Aye,we nephrologists seek it everywhere.
Couple of weeks ago, NephJC discussed the intriguing urinary biomarker study for diagnosis of AIN by @dmoledina et al.
✳️#NephJC catch-up✳️of the damned, elusive chase!👇 pic.twitter.com/OsiMjOaKEA
Basic science week - catch up in only Ten Tweets here.
Welcome to #TenTweetNephJC
— Nephrology Jrnl Club (@NephJC) October 26, 2022
✳️10 tweets #NephJC catch-up ✳️
Perplexed by how gene dosage plays a role in ADPKD? Fascinated by futuristic stories of miRNA,CRISPR & want to see an application closer to daily life?
Read on!Here’s some good news for the ADPKD patient in your clinic. pic.twitter.com/44iFttuRJK
